$CVM Cashflow Statement | Understand Stock

$CVM

$1.57 -$0.02 (1.26%) Close

$CVM Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Statements of cash flows

In millions of USD, except per-share amounts

	FY2025 12 months to Sep 30, 2025	FY2024 12 months to Sep 30, 2024	FY2023 12 months to Sep 30, 2023	FY2022 12 months to Sep 30, 2022	FY2021 12 months to Sep 30, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Non-cash lease expense
Non-cash lease expense, net of lease payments
Share-based payments for services
Equity based compensation
Common stock contributed to 401(k) plan
Shares issued for settlement of clinical research costs
Gain on short-term investments
Loss on derivative instruments
Warrant inducement expense
Gain on short term investments
Gain on derivative instruments
Modification of warrants
Impairment loss on abandonment of patents
Loss on Receivables
Shares issued for settlement of clinic development costs
Loss on patent impairment
(Increase)/decrease in assets:
Receivables
Prepaid expenses
Supplies used for R&D and manufacturing
Deposits
Increase/(decrease) in liabilities:
Accounts payable
Accrued expenses
Other liabilities
Due to employees
Net cash used in operating activities

CASH FLOWS FROM INVESTING ACTIVITIES:
Net purchases of U.S. Treasury Bills
Net sales (purchases) of US Treasury bills
Proceeds from maturity of U.S. Treasury Bills
Purchases of property and equipment
Expenditures for patent costs
Net cash used in investing activities

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants
Proceeds from landlord funding of leasehold improvements
Proceeds from issuance of common stock
Proceeds from issuance of common stock and pre-funded warrants
Payments of stock issuance costs
Proceeds from the exercise of warrants
Proceeds from the exercise of options
Proceeds from landlord funding of lease improvements
Proceeds from the purchase of stock by officers and directors

Payments on obligations under finance leases
Proceeds from related party loans
Payments of related party loans
Proceeds from notes payable
Payments of notes payable
Net cash provided by financing activities
NET INCREASE IN CASH AND CASH EQUIVALENTS
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR
CASH AND CASH EQUIVALENTS, END OF YEAR
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Property and equipment included in accrued expenses and accounts payable
Property and equipment purchases included in current liabilities
Changes to right of use assets and liabilities
Capitalized patent costs included in current liabilities
Obligations paid with issuance of common stock
Assets purchased under finance leases
Fair value of warrants liabilities on date of exercise
Financing costs included in accounts payable
Fair value of warrant liabilities on date of exercise
Prepaid consulting services paid with issuance of common stock
Consulting services paid with issuance of common stock
Exercise of derivative liabilities
Accrued consulting services to be paid with common stock
Finance lease obligation included in accounts payable
Financing costs included in current liabilities

SUPPLEMENTAL DISCLOSURE OF CASH FLOWS:
Cash paid for interest

Comments